Brigham and Women's Hospital
Introduction
Brigham And Women'S Hospital is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-institution"> [@bateman2012]
<div class="infobox-header">Brigham and Women's Hospital</div> [@selkoe2016]
<div class="infobox-image"></div> [@holtzman2016]
<div class="infobox-data"> [@sperling2011]
<div class="infobox-row"><strong>Location:</strong> Boston, Massachusetts, USA</div> [@masters2015]
<div class="infobox-row"><strong>Type:</strong> Academic Medical Center</div> [@de2016]
<div class="infobox-row"><strong>Founded:</strong> 1994</div> [@long2019]
<div class="infobox-row"><strong>Affiliation:</strong> Harvard Medical School</div>
<div class="infobox-row"><strong>Website:</strong> https://www.brighamandwomens.org brighamandwomens.org</div>
</div>
</div>
Overview
Mermaid diagram (expand to render)
Brigham and Women's Hospital (BWH) is a world-renowned academic medical center affiliated with Harvard Medical School and one of the leading institutions for neurodegenerative disease research in the United States. Located in Boston, Massachusetts, BWH is consistently ranked among the top hospitals in the nation and serves as a major referral center for complex neurological conditions.
Neurodegenerative Disease Research Programs
Alzheimer's Disease Research
BWH is home to one of the nation's premier [Alzheimer's disease](/diseases/alzheimers-disease) research programs. The Brigham and Women's Hospital Alzheimer's Disease Research Center (ADRC) conducts groundbreaking clinical trials and translational research focused on:
- Early Detection and Prevention: Development of biomarker-based screening approaches for preclinical Alzheimer's disease
- Clinical Trials: Pioneering immunotherapy approaches including anti-amyloid and anti-[tau](/proteins/tau) therapies
- Neuroimaging: Advanced PET and MRI techniques for tracking disease progression
- Genetic Risk Factors: Investigation of [APOE](/proteins/apoe-protein) and other genetic modifiers of Alzheimer's risk
The hospital houses the
Center for Alzheimer Research and Treatment (CART), which focuses on novel therapeutic strategies and longitudinal studies of cognitive decline.
Neurology Department
The Department of Neurology at BWH provides comprehensive care for patients with:
- Alzheimer's disease and related dementias
- [Parkinson's disease](/diseases/parkinsons-disease) and movement disorders
- Amyotrophic lateral sclerosis (ALS)
- Multiple sclerosis
- Stroke and cerebrovascular disease
Key Research Centers
- Ann Romney Center for Neurologic Diseases: Focused on understanding the biological mechanisms of neurological diseases
- Martinos Center for Biomedical Imaging: State-of-the-art neuroimaging facilities
- Center for Dementia Research: Comprehensive program studying Alzheimer's and related dementias
Notable Researchers
Reisa A. Sperling, MD, MMSc
- Director of the Center for Alzheimer Research and Treatment at BWH
- Professor of Neurology at Harvard Medical School
- Principal Investigator of multiple NIH-funded Alzheimer's disease research projects
- Key focus: Preclinical Alzheimer's disease, amyloid imaging, clinical trials
- Notable Publications:
- "The A4 Study: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease" (NEJM, 2020)
- "Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease" (NEJM, 2012)
Dennis J. Selkoe, MD
- Co-Director of the Ann Romney Center for Neurologic Diseases
- Professor of Neurology and Neuroscience at Harvard Medical School
- World-renowned expert on Alzheimer's disease pathogenesis
- Key discoveries: Identification of [Aβ](/proteins/amyloid-beta) as the Alzheimer's disease amyloid, characterization of [APP](/entities/app-protein) metabolism
- Notable Publications:
- "Soluble oligomers of the amyloid β-protein are the proximate neurotoxins in Alzheimer's disease" (Nature, 1998)
- Over 300 publications on Alzheimer's disease mechanisms
Other Key Faculty
| Researcher | Area of Focus | Notable Contributions |
|-----------|---------------|----------------------|
| Dr. Michael E. Dickerson | Movement disorders, DBS | Parkinson's disease deep brain stimulation |
| Dr. Alejandro L. Matute | Neuroimmunology | Multiple sclerosis research |
| Dr. Sarah C. Y. Huang | Cognitive neurology | Early detection biomarkers |
| Dr. Bradley T. Hyman | Tau biology | Neurofibrillary tangle mechanisms |
| Dr. Michael A. Schwarzschild | Parkinson's disease | LRRK2 and alpha-synuclein research |
Research Leadership
BWH neurology research is led by department chief Dr. Maria D. G. Fahy, who oversees a research portfolio of over $50M annually from NIH and foundation sources.
Clinical Programs
Memory Disorders Unit
The Memory Disorders Unit at BWH provides:
- Comprehensive neuropsychological evaluation
- State-of-the-art neuroimaging
- Access to cutting-edge clinical trials
- Multidisciplinary care coordination
Movement Disorders Program
Expert care for:
- [Parkinson's disease](/diseases/parkinsons-disease) Huntington's disease
- Essential tremor
- Dystonia
Training and Education
BWH trains the next generation of neurologists and neuroscience researchers through:
- Neurology residency program
- Fellowship programs in cognitive neurology, movement disorders, and neuroimmunology
- Postdoctoral research training opportunities
Research Facilities
Ann Romney Center
State-of-the-art research facilities including:
- Clinical research unit
- Biomarker laboratory
- Data management center
Martinos Center for Biomedical Imaging
- 3T and 7T MRI scanners
- PET imaging suite
- Magnetoencephalography (MEG)
- Transcranial magnetic stimulation (TMS) laboratory
Collaborations
BWH collaborates extensively with:
- Massachusetts General Hospital (neighbor and Harvard affiliate)
- Harvard Medical School
- Massachusetts Institute of Technology (MIT)
- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- National Institute on Aging (NIA)
Disease Focus
| Disease | Research Focus |
|---------|---------------|
| Alzheimer's Disease | Amyloid and [tau](/proteins/tau) mechanisms, biomarkers, clinical trials |
| Parkinson's Disease | [Alpha-synuclein](/proteins/alpha-synuclein), Lewy body disease |
| ALS | [TDP-43](/proteins/tdp-43) pathology, genetic modifiers |
| Frontotemporal Dementia | GRN, [C9orf72](/entities/c9orf72), [tau](/proteins/tau) |
| Vascular Cognitive Impairment | Cerebrovascular contributions to dementia |
Recent Research Highlights
A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease): Landmark prevention trial led by Dr. Reisa Sperling
Dominantly Inherited Alzheimer's Disease Network (DIAN): Characterization of preclinical Alzheimer's in genetic forms
Immunotherapy Development: Pioneering work on monoclonal antibodies targeting [Aβ](/proteins/amyloid-beta) and tau
Biomarker Validation: Development of plasma p-tau181 and other blood-based biomarkers
Research Infrastructure and Resources
Clinical Research Infrastructure
BWH maintains a robust clinical research infrastructure for neurodegenerative disease studies:
- Clinical Trials Unit: Dedicated staff for patient recruitment, data management, and regulatory compliance
- Sample Repository: Biospecimen bank including CSF, blood, and brain tissue
- Data Analytics Core: Bioinformatics support for large-scale data analysis
Translational Research Programs
Center for Alzheimer Research and Treatment (CART)
The CART program at BWH represents one of the most productive Alzheimer's research programs in the world[@sperling2020]:
| Program | Focus | Status |
|---------|-------|--------|
| A4 Study | Anti-amyloid therapy in preclinical AD | Completed |
| DIAN | Dominantly inherited AD | Ongoing |
| LEARN | Prevention in secondary prevention | Ongoing |
| Anti-tau trials | Tau-targeted immunotherapy | Phase 2 |
Ann Romney Center for Neurologic Diseases
The Ann Romney Center brings together interdisciplinary research teams:
- Basic Science: Molecular and cellular biology of neurodegeneration
- Translational Research: Drug discovery and biomarker development
- Clinical Research: Trial design and patient outcomes research
- Computational Biology: AI and machine learning approaches
Neuroimaging Capabilities
The Martinos Center for Biomedical Imaging provides state-of-the-art neuroimaging:
| Modality | Capabilities | Applications |
|----------|--------------|--------------|
| PET | Amyloid, tau, dopamine tracers | Diagnostic, research |
| MRI | Structural, functional, diffusion | Disease monitoring |
| MEG | Millisecond brain dynamics | Epilepsy, cognition |
| TMS | Non-invasive brain stimulation | Therapy development |
Major Research Contributions
Alzheimer's Disease Research
BWH researchers have made foundational contributions to Alzheimer's disease understanding:
Amyloid Hypothesis Validation: Dennis Selkoe's work established the centrality of Aβ oligomers in AD pathogenesis
Preclinical AD Framework: Reisa Sperling's research defined the stages before clinical symptoms
Immunotherapy Pioneering: Led first-in-human studies of anti-amyloid antibodies
Biomarker Development: Validated CSF and plasma biomarkers for diagnosis and monitoringParkinson's Disease Research
BWH contributes significantly to PD research:
- Alpha-synuclein biology: Understanding aggregation mechanisms
- LRRK2 research: Genetic and therapeutic studies
- Clinical trials: Movement disorder clinical research
- Deep brain stimulation: Surgical therapy development
ALS and Motor Neuron Disease
BWH has an active ALS research program:
- Genetic studies: SOD1, C9orf72, and novel gene discovery
- Biomarker development: Neurofilament light chain validation
- Clinical trials: Participation in NEALS consortium
- Patient care: Multidisciplinary ALS clinic
Leadership in Clinical Trials
Active Clinical Trials
BWH currently runs numerous clinical trials across neurodegenerative diseases:
| Trial | Phase | Therapy | Target |
|-------|-------|---------|--------|
| Anti-amyloid antibodies | Phase 3 | Various | Aβ plaque |
| Anti-tau antibodies | Phase 2 | Various | Tau tangles |
| BACE inhibitors | Phase 3 | Various | Aβ production |
| Disease modifiers | Phase 1/2 | Various | Multiple |
Trial Infrastructure
- Patient recruitment: Robust pipeline of interested participants
- Regulatory expertise: IND experience with FDA
- Data management: Electronic data capture and quality control
- Monitoring: Internal monitoring and audit capabilities
Training and Education Programs
Neurology Residency
BWH offers a categorical neurology residency program training the next generation of neurologists:
- Clinical training: Hands-on experience with diverse patient populations
- Research exposure: Introduction to basic and clinical research
- Subspecialty rotations: Memory disorders, movement disorders, neuroimmunology
Fellowship Programs
BWH provides advanced fellowship training in:
- Cognitive Neurology: Behavioral neurology and neuropsychiatry
- Movement Disorders: Parkinson's disease and related conditions
- Neuroimaging: Advanced imaging research training
- Clinical Trials: Methodology and conduct
Future Directions
Precision Medicine Initiatives
BWH is advancing precision medicine approaches:
- Genetic stratification: Tailoring therapy based on genotype
- Biomarker-driven trials: Enriching trials with biomarker-positive patients
- Personalized prevention: Individualized risk reduction strategies
Technology Integration
BWH is incorporating emerging technologies:
- Digital health: Wearable devices and smartphone-based monitoring
- Artificial intelligence: Predictive models for diagnosis and progression
- Multi-omics: Integrating genomic, proteomic, and metabolomic data
Research Expansion
BWH is expanding its research portfolio:
- Neuroinflammation: Understanding the role of immune responses
- Systems neuroscience: Circuit-level understanding of dysfunction
- Regenerative approaches: Stem cell and gene therapy development
Background
The study of Brigham And Women'S Hospital has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- The Amyloid Cascade Hypothesis
- [Reisa Sperling](/researchers/reisa-sperling)
- [Dennis Selkoe](/researchers/dennis-selkoe)
- [Harvard Medical School](institutions/harvard-medical-school)
- [Massachusetts General Hospital](institutions/massachusetts-general-hospital)
- Biomarkers of Alzheimer Disease
- [clinical-trials](/clinical-trials)
External Links
- [Brigham and Women's Hospital](https://www.brighamandwomens.org)
- [Center for Alzheimer Research and Treatment](https://www.brighamandwomens.org/neurology/alzheimers-center)
- [Ann Romney Center for Neurologic Diseases](https://www.brighamandwomens.org/research/ann-romney-center)
- [Harvard Medical School Department of Neurology](https://www.hms.harvard.edu/dept/neurology)
References
Sperling RA, et al, "The A4 Study: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease." New England Journal of Medicine (2020)
Bateman RJ, et al, "Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease." New England Journal of Medicine (2012)
Selkoe DJ, Hardy J, "The amyloid hypothesis of Alzheimer's disease at 25 years." EMBO Molecular Medicine (2016)
Holtzman DM, et al, "Alzheimer's disease: the challenge of the second century." Science Translational Medicine (2016)
Sperling RA, et al, "Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Alzheimer's & Dementia (2011)
Masters CL, et al, "Alzheimer's disease." Nature Reviews Disease Primers (2015)
De Strooper B, Karran E, "The Cellular Phase of Alzheimer's Disease." Cell (2016)
Long JM, Holtzman DM, "Alzheimer Disease: An Update on Pathobiology and Treatment Strategies." Cell (2019)